FUSE — Foundry for Urologic Science and Entrepreneurship

Clinical Excellence ● Entrepreneurial Thinking ● Impact-Driven AI

FUSE

Foundry for Urologic Science & Entrepreneurship

We are building a world-class innovation hub where excellence in medical research meets entrepreneurship and AI. By bringing together top-tier clinicians, researchers, entrepreneurs, investors, industry partners and AI specialists, we transform scientific discoveries into real-world impact, accelerating the development of new technologies, therapies, companies, and models of care that improve patients' lives.

Discover the Model Talk to Us

What We Build

Two tracks. One mission. One legal structure.

FUSE runs two distinct innovation tracks under one roof, sharing one overarching mission: Clinical Excellence.

Track One, From Year 1

Open Innovation

A Curation Model, The Accelerator

The idea originates outside. We accelerate it.

We select existing founder-led teams with proven ideas and accelerate their development, inside a real hospital environment.

Selection · Capital · Clinical Access · Data · Mentorship

Track Two

Foundry

A Creation Model, The Venture Studio

The idea originates inside. We are co-founder and builder.

We originate ideas internally, recruit talent to execute them, and build companies from scratch.

Idea Generation · Talent recruitment · Capital · Data · IP Ownership · Co-Building

Permanent Foundation, Data Platform

FUSE's primary competitive advantage is its unprecedented patient volume. FUSE operationalizes that advantage through a structured, anonymized, CNIL-compliant data infrastructure, built before either track launches, and maintained with rigour every day.

"In the coming years, artificial intelligence will be the main driver of innovation in healthcare. It will be the key to major advances in medical diagnosis, prevention, and treatment, as well as in the organization of care."

Prof. Michaël Peyromaure , Head of Urology, AP-HP Hôpital Cochin; Medical Director, Uroplus Foundation

Why FUSE

A Unique Value Proposition

The Department of Urology at AP-HP Cochin, led by Pr. Michaël Peyromaure, combines exceptional patient volume, structured clinical data, and a strong commitment to innovation and AI. Together with a dedicated urology foundation providing private funding and operational flexibility, it offers a uniquely favorable environment to build a world-class HealthTech innovation platform inspired by leading Silicon Valley accelerators experienced firsthand by members of our founding team.

Clinical Volume as Infrastructure

Healthcare innovation depends on access to patients, clinical expertise, and real-world evidence. FUSE brings these assets together to develop, validate, and scale solutions that improve patient care.

Disease-Area Focus

FUSE is a focused, domain-driven platform. Every startup is anchored in focused verticals, ensuring relevance, coherence, and the attraction of top founders and researchers. The journey begins with urology and will expand to other HealthTech domains over time.

Dual-Track Architecture

A unique combination of an accelerator and a venture studio within a single HealthTech platform creates a powerful engine for innovation. Track 1 generates ventures, reputation, and deal flow. Track 2 creates intellectual property, partnerships, clinical excellence, and long-term value.

Private, Independent, Focused

FUSE operates as an independent SAS subsidiary, with its own governance, designed to reach operational break-even. Free from the procurement cycles and political constraints of public institutions, it moves at the speed innovation demands.

"Seeing the concepts I teach in AI at École Polytechnique translated into real-world impact is deeply meaningful to me. My journey with Sonio convinced me that entrepreneurship is one of the fastest ways to accelerate the development and adoption of innovations that can improve millions of patients' lives. Joining forces with leading clinicians offers an unique opportunity to maximize the positive impact we can have on people's lives thanks to AI."

Prof. Erwan Lepennec , Professor, École Polytechnique; Co-Founder, FUSE

The Team

People you can bet on.

Clinical authority. Entrepreneurial track record. Legal and regulatory rigour. Statistical depth and AI authority. Each co-founder brings a dimension that is rare on its own, together, they cover every axis a HealthTech innovation engine requires.

Prof. Michaël Peyromaure

Medical Director & Co-Founder

Head of Urology, AP-HP Hôpital Cochin, Paris Medical Director, Uroplus Foundation Leading French urologist in prostate cancer Exceptional patient volume & clinical access

Profile

Prof. Erwan Lepennec

Scientific Advisor & Co-Founder

Professor, École Polytechnique, Applied Mathematics Head of CMAP Head of MScT Data Science & AI, Polytechnique Executive Education Co-Founder Sonio, Exit to Samsung $92M (2025) Co-Founder Let it Wave, Exit (2008) ENS Cachan, DEA · Agrégation · MVA

Olivier Carteret

CEO & Co-Founder

Founder & CEO Aristeia, Founded 2001, exit 2016 Portfolio Founder Former Olympic Athlete UC Berkeley Haas, MBA ESCP Europe, Master's (Grandes Écoles)

Advisory Board

Bruno Derieux

Legal & Governance Advisor

Partner Corporate / M&A, Linklaters LLP Deal structuring & governance expertise Complex innovation engine legal architecture Panthéon-Assas Paris 2 / University of Oxford, Faculty of Law

Profile

Hélène Mathieu

Health Innovation Networks

Resonance Health Europe, Cross-border health innovation network

Prof. Laurent Lantieri

Surgical Excellence & Medical Innovation

Chief of Plastic Reconstructive Surgery, Hôpital Européen Georges Pompidou

Investment Thesis

A strategic infrastructure investment.

"We have the patients, the data, the space, and the top-tier medical specialists. What we build now is the engine that turns these assets into Europe's most important innovation platform in prostate cancer, and possibly in HealthTech."

Olivier Carteret, CEO, FUSE

The Question Is Not IRR

The right question is: what does it cost to become the leading European institution in HealthTech innovation, and what is that position worth? The answer reframes what investment means.

Financial Returns Are Real

At 4 companies per cohort and 1 cohort per year, total program investment over 5 years is approximately €7M. A single exit at €500M valuation on a 7% stake returns €35M. Returns are possible. They are not the primary objective.

Strategic Value Is Permanent

Recognition as Europe's leading urology institution. Philanthropic and EU grant leverage. Corporate partnerships at premium terms. A proprietary data asset that compounds with every cohort. These do not appear on a cap table, but they are durable.